The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of albumin-bound rapamycin nanoparticles in the treatment of bacillus calmette-guerin refractory non-muscle invasive transitional cell bladder cancer.
 
James M. McKiernan
Speakers' Bureau - Astellas Pharma
Research Funding - Exosome Diagnostics; Sanofi
 
Ifeanyi Onyeji
No Relationships to Disclose
 
Danny Lascano
No Relationships to Disclose
 
Jennifer Ahn
No Relationships to Disclose
 
Neil Desai
Employment - AADi; Celgene
Leadership - AADi; Celgene
Stock and Other Ownership Interests - AADi; Celgene
Patents, Royalties, Other Intellectual Property - AADi
 
Cory Abate-Shen
Research Funding - LabCorp
Patents, Royalties, Other Intellectual Property - LabCorp - licensing payments (under 5K)
 
Dara Denise Holder
No Relationships to Disclose
 
Arindam RoyChoudhury
No Relationships to Disclose
 
Sam Chang
Consulting or Advisory Role - Astellas Pharma; Bayer; Gerson Lehrman Group; Janssen
Research Funding - CG Oncology
 
Guarionex Joel DeCastro
No Relationships to Disclose